Disorders of fatty acid oxidation

Handbook of Clinical Neurology

Volumn 113, Issue , 2013, Pages 1675-1688

  Tein, Ingrid ^a  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876831776     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-59565-2.00035-6     Document Type: Chapter

References (123)

1. Al-Odaib A., Shneider B.L., Bennett M.J., et al. A defect in the transport of long-chain fatty acids associated with acute liver failure. N Engl J Med 1998, 339:1752-1757.
2. Andresen B.S., Bross P., Vianey-Saban C., et al. Cloning and characterization of human very-long-chain acyl-CoA dehydrogenase cDNA, chromosomal assignment of the gene and identification in four patients of nine different mutations within the VLCAD gene. Hum Mol Genet 1996, 5:461-472.
3. Andresen B.S., Vianey-Saban C., Bross P., et al. The mutational spectrum in very long-chain acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis 1996, 19:169-172.
4. Aoyama T., Souri M., Ushikubo S., et al. Purification of human very-long-chain acyl-coenzyme A dehydrogenase and characterization of its deficiency in seven patients. J Clin Invest 1995, 95:2465-2473.
5. Bell A.W., Thompson G.E. Free fatty acid oxidation in bovine muscle in vivo: effects of cold exposure and feeding. Am J Physiol 1979, 237:E309-E315.
6. Bennett M.J. Pathophysiology of fatty acid oxidation disorders. J Inherit Metab Dis 2010, 33:533-537.
7. Bennett M.J., Worthy E., Pollitt R.J. The incidence and presentation of dicarboxylic aciduria. J Inherit Metab Dis 1987, 10:241-242.
8. Bennett M.J., Weinberger M.J., Kobori J.A., et al. Mitochondrial short-chain L-3-hydroxybutyryl-CoA dehydrogenase deficiency: a new defect of fatty acid oxidation. Pediatr Res 1996, 39:185-188.
9. Bennett M.J., Spotswood S.D., Ross K.F., et al. Fatal hepatic short-chain L-3-hydroxyacyl-coenzyme A dehydrogenase deficiency: clinical, biochemical, and pathological studies on three subjects with this recently identified disorder of mitochondrial beta-oxidation. Pediatr Dev Pathol 1999, 2:337-345.
10. Bennett M.J., Russell L.K., Tokunaga C., et al. Reye-like syndrome resulting from novel missense mutations in mitochondrial medium- and short-chain L-3-hydroxy-acyl-CoA dehydrogenase. Mol Genet Metab 2006, 89:74-79.
11. Bhala A., Willi S.M., Rinaldo P., et al. Clinical and biochemical characterization of short-chain acyl-coenzyme A dehydrogenase deficiency. J Pediatr 1995, 126:910-915.
12. Blakemore A.I.F., Singleton H., Pollitt R.J., et al. Frequency of the G985 MCAD mutation in the general population. Lancet 1991, 337:298-299.
13. Bremer J. Carnitine-metabolism and functions. Physiol Rev 1983, 63:1420-1480.
14. Cahill G.F. Starvation in man. N Engl J Med 1970, 282:668-675.
15. Cederbaum S.D., Koo-McCoy S., Tein I., et al. Carnitine membrane transporter deficiency: a long-term follow up and OCTN2 mutation in the first documented case of primary carnitine deficiency. Mol Genet Metab 2002, 77:195-201.
16. Colevas A.D., Edwards J.L., Hruban R.H., et al. Glutaric acidemia type II: comparison of pathologic features in two infants. Arch Pathol Lab Med 1988, 112:1133-1139.
17. Corkey B.E., Hale D.E., Glennon M.C., et al. Relationship between unusual hepatic acyl coenzyme A profiles and the pathogenesis of Reye syndrome. J Clin Invest 1988, 82:782-788.
18. Corydon M.J., Gregersen N., Lehnert W., et al. Ethylmalonic aciduria is associated with an amino acid variant of short chain acyl-coenzyme A dehydrogenase. Pediatr Res 1996, 39:1059-1066.
19. Corydon M.J., Vockley J., Rinaldo P., et al. Role of common gene variations in the molecular pathogenesis of short-chain acyl-CoA dehydrogenase deficiency. Pediatr Res 2001, 49:18-23.
20. Demaugre F., Bonnefont J.P., Colonna M., et al. Infantile form of carnitine palmitoyltransferase II deficiency with hepatomuscular symptoms and sudden death. Physiopathological approach to carnitine palmitoyltransferase II deficiencies. J Clin Invest 1991, 87:859-864.
21. DiMauro S., Papadimitriou A. Carnitine palmitoyltransferase deficiency. Myology 1986, Vol. 2. McGraw-Hill, New York.
22. Dionisi-Vici C., Burlina A.B., Bertini E., et al. Progressive neuropathy and recurrent myoglobinuria in a child with long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. J Pediatr 1991, 118:744-746.
23. Djouadi F., Bastin J. PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders. J Inherit Metab Dis 2008, 31:217.
24. Elpeleg O.N., Joseph A., Branski D., et al. Recurrent metabolic decompensation in profound carnitine palmitoyltransferase II deficiency. J Pediatr 1993, 122:917-919.
25. Essen B. Glycogen depletion of different types in human skeletal muscle during intermittent and continuous exercise. Acta Physiol Scand 1978, 103:446-455.
26. Feige J.N., Gelman L., Michalik L., et al. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 2006, 45:120.
27. Felig P., Wahren J. Fuel homeostasis in exercise. N Engl J Med 1975, 293:1078-1084.
28. Fernandes J., Smit G. The glycogen storage diseases. Inborn error of metabolic diseases, diagnosis and treatment 2001, 85-118. Springer, New York. 3rd edn. J. Fernandes, J.M. Saudubray, C. Van den Berghe (Eds.).
29. Fingerhut R., Ensenauer R., Röschinger W., et al. Stability of acylcarnitines and free carnitine in dried blood samples: implications for retrospective diagnosis of inborn errors of metabolism and neonatal screening for carnitine transporter deficiency. Anal Chem 2009, 81:3571.
30. Fukao T., Yamaguchi S., Orii T., et al. Molecular basis of beta-ketothiolase deficiency: mutations and polymorphisms in the human mitochondrial acetoacetyl-coenzyme A thiolase gene. Hum Mutat 1995, 5:113-120.
31. Fukao T., Song X.Q., Yamaguchi S., et al. Identification of three novel frameshift mutations (83delAT), 754insCT, and 435+1G to A) of mitochondrial acetoacetyl-coenzyme A thiolase gene in two Swiss patients with CRM-negative beta-ketothiolase deficiency. Hum Mutat 1997, 9:277-278.
32. Gempel K., Topaloglu H., Talim B., et al. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain 2007, 130:2037-2044.
33. Gibson E.M., Breuer J., Nyhan W.L. 3-Hydroxy-3-methylglutaryl-coenzyme A lyase deficiency: review of 18 reported patients. Eur J Pediatr 1988, 148:180-186.
34. Gillingham M.B., Mills M.D., Vancalcar S.C., et al. DHA supplementation in children with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. 7th International Congress of Inborn Errors of Metabolism 1997, May 21-25, Vienna, Austria, (Abstr).
35. Gillingham M., Van Calcar S., Ney D., et al. Dietary management of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD): a case report and survey. J Inherit Metab Dis 1999, 22:123-131.
36. Glasgow A.M., Engel A.G., Bier D.M., et al. Hypoglycemia, hepatic dysfunction, muscle weakness, cardiomyopathy, free carnitine deficiency and long-chain acylcarnitine excess responsive to medium-chain triglyceride diet. Pediatr Res 1983, 17:319-326.
37. Gollnick P.D. Metabolism of substrates: energy substrate metabolism during exercise and as modified by training. Fed Proc 1985, 44:353-357.
38. Goodman S.I., Bemelen K.F., Frerman F.E. Human cDNA encoding ETF dehydrogenase (ETF; ubiquinone oxidoreductase), and mutations in glutaric acidemia type II. Progress in Clinical and Biological Research. New Developments in Fatty Acid Oxidation 1992, Vol. 375. Wiley-Liss, New York. P.M. Coates, K. Tanaka (Eds.).
39. Gregersen N., Wintzensen H., Kølvraa S., et al. C6-C10-dicarboxylic aciduria: investigations of a patient with riboflavin responsive multiple acyl-CoA dehydrogenation defects. Pediatr Res 1982, 16:861-868.
40. Gregersen N., Andresen B.S., Bross P., et al. Characterization of a disease-causing Lys329 to Glu mutation in 16 patients with medium-chain acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis 1991, 14:314-316.
41. Gregersen N., Winter V.S., Corydon M.J., et al. Characterization of four new mutations in the short-chain acyl-CoA dehydrogenase (SCAD) gene in two patients with SCAD deficiency (abstract). J Inherit Metab Dis 1996, 19.
42. Gregersen N., Winter V.S., Corydon M.J., et al. Identification of four new mutations in the short-chain acyl-CoA dehydrogenase (SCAD) gene in two patients: one of the variant alleles, 511C->T, is present at an unexpectedly high frequency in the general population, as was the case for 625G->A, together conferring susceptibility to ethylmalonic aciduria. Hum Mol Genet 1998, 7:619-627.
43. Gregersen N., Andresen B.S., Pedersen C.B., et al. Mitochondrial fatty acid oxidation defects - remaining challenges. J Inherit Metab Dis 2008, 31:643.
44. Haack T.B., Danhauser K., Haberberger B., et al. Exome sequencing identifies ACAD9 mutations as a cause of complex I deficiency. Nature Genet 2010, 42:1131-1134.
45. Hale D.E., Bennett M.J. Fatty acid oxidation disorders: a new class of metabolic diseases. J Pediatr 1992, 121:1-11.
46. Hale D.E., Batshaw M.L., Coates P.M., et al. Long-chain acyl coenzyme A dehydrogenase deficiency: an inherited cause of nonketotic hypoglycemia. Pediatr Res 1985, 19:666-671.
47. Hale D.E., Stanley C.A., Coates P.M. The long-chain acyl-CoA dehydrogenase deficiency. Progress in Clinical and Biological Research. Fatty Acid Oxidation: Clinical, Biochemical and Molecular Aspects 1990, Vol. 321:303-311. Alan R. Liss, New York. K. Tanaka, P.M. Coates (Eds.).
48. Hale D.E., Thorpe C., Braat K., et al. The L-3-hydroxyacyl-CoA dehydrogenase deficiency. Progress in Clinical and Biological Research. Fatty Acid Oxidation: Clinical, Biochemical and Molecular Aspects 1990, Vol. 321:503-510. Alan R. Liss, New York. K. Tanaka, P.M. Coates (Eds.).
49. Harding C.O., Gillingham M.B., Van Calcar S.C., et al. Docosahexaenoic acid and retinal function in children with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. J Inherit Metab Dis 1999, 22:276-280.
50. Hayde M., Widhalm K. Effects of cornstarch treatment in very young children with type I glycogen storage diseases. Eur J Pediatr 1990, 149:630-633.
51. He M., Rutledge S.L., Kelly D.R., et al. A new genetic disorder in mitochondrial fatty acid beta-oxidation: ACAD9 deficiency. Am J Hum Genet 2007, 81:87-103.
52. Hug G., Bove K.E., Soukup S. Lethal neonatal multiorgan deficiency of carnitine palmitoyltransferase II. N Engl J Med 1991, 325:1862-1864.
53. Ibdah J.A., Tein I., Dionisi-Vici C., et al. Mild trifunctional protein deficiency is associated with progressive neuropathy and myopathy and suggests a novel genotype-phenotype correlation. J Clin Invest 1998, 102:1193-1199.
54. Ibdah J.A., Zhao M., Hill I., et al. The association between maternal liver disease and the common mutation in mitochondrial trifunctional protein is significant. Hepatology 1998, 28:316. (Abstr).
55. Ibdah J.A., Bennett M.J., Rinaldo P., et al. A fetal fatty acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med 1999, 340:1723-1731.
56. Inoue D., Pappano A.J. L-palmitoylcarnitine and calcium ions act similarly on excitatory ionic currents in avian ventricular muscle. Circ Res 1983, 52:625-634.
57. Isaacs J.D., Sims H.F., Powell C.K., et al. Maternal acute fatty liver of pregnancy associated with fetal trifunctional protein deficiency: molecular characterization of a novel mutant allele. Pediatr Res 1996, 40:393-398.
58. Isackson P.J., Bennett M.J., Lichter U., et al. CPT 2 gene mutations resulting in lethal neonatal or severe infantile carnitine palmitoyltransferase II deficiency. Mol Genet Metab 2008, 94:422-427.
59. Johnson R.E., Possmore R., Sargent F. Multiple factors in experimental human ketosis. Arch Intern Med 1961, 107:43-50.
60. Kamijo T., Indo Y., Souri M., et al. Medium-chain 3-ketoacyl-coenzyme A thiolase deficiency: a new disorder of mitochondrial fatty acid β-oxidation. Pediatr Res 1997, 42:569-576.
61. Kerner J., Bieber L.L. A radioisotopic exchange method for quantitation of short-chain (acid soluble) acylcarnitines. Anal Biochem 1983, 134:459-466.
62. Kobayashi A., Jiang L.L., Hashimoto T. Two mitochondrial 3-hydroxyacyl-CoA dehydrogenases in bovine liver. J Biochem (Tokyo) 1996, 119:775-782.
63. Lamhonwah A.M., Olpin S.E., Pollitt R.J., et al. Novel OCTN2 mutations: no genotype-phenotype correlations: early carnitine therapy prevents cardiomyopathy. Am J Med Genet 2002, 111:271-284.
64. Lee C.H., Olson P., Evans R.M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003, 144:2201-2207.
65. Mak I.T., Kramer J.H., Weglicki W.B. Potentiation of free radical-induced lipid peroxidative injury to sarcolemmal membranes by lipid amphiphiles. J Biol Chem 1986, 26:1153-1164.
66. Millington D.S. New methods for the analysis of acylcarnitines and acyl-coenzyme A compounds. Mass Spectrometry in Biomedical Research 1986, Wiley, New York, ch. 7. S.J. Gaskell (Ed.).
67. Millington D.S., Terada N., Chace D.H., et al. The role of tandem mass spectrometry in the diagnosis of fatty acid oxidation disorders. Progress in Clinical and Biological Research. New Developments in Fatty Acid Oxidation 1992, Vol. 375. Wiley-Liss, New York. P.M. Coates, K. Tanaka (Eds.).
68. Mitchell G.A., Fukao T. Inborn errors of ketone body metabolism. The Metabolic and Molecular Basis of Inherited Disease 2001, 2327-2356. McGraw-Hill, New York. 8th edn. C. Scriver, A.L. Beaudet, W. Sly (Eds.).
69. Monk J.P., Todd P.A. Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs 1987, 33:539-576.
70. Naito E., Indo Y., Tanaka K. Identification of two variant short chain acyl-coenzyme A dehydrogenase alleles, each containing a different point mutation in a patient with short chain acyl-coenzyme A dehydrogenase deficiency. J Clin Invest 1990, 85:1575-1582.
71. Ogilvie I., Pourfarzam M., Jackson S., et al. Very long-chain acyl coenzyme A dehydrogenase deficiency presenting with exercise-induced myoglobinuria. Neurology 1994, 44:467-473.
72. Pedersen C.B., Kolvraa S., Kolvraa A., et al. The ACADS gene variation spectrum in 114 patients with short-chain acyl-CoA dehydrogenase (SCAD) deficiency is dominated by missense variations leading to protein misfolding at the cellular level. Hum Genet 2008, 124:43-56.
73. Peters J.M., Aoyama T., Burns A.M., et al. Bezafibrate is a dual ligand for PPARalpha and PPARbeta: studies using null mice. Biochim Biophys Acta 2003, 1632:80-89.
74. Poll-The B.T., Duran M., Mousson B., et al. Carnitine palmitoyl transferase I deficiency: is there a diagnostic dicarboxylic aciduria? 1992, 128. Abstract,.
75. Pretorius C.J., Son G.G.L., Bonnici F., et al. Two siblings with episodic ketoacidosis and decreased activity of succinyl-CoA-3-ketoacid CoA-transferase in cultured fibroblasts. J Inherit Metab Dis 1996, 19:296-300.
76. Renaud D.L., Edwards V., Wilson G.J., et al. Glucose-free medium exacerbates microvesicular steatosis in cultured skin fibroblasts of genetic defects in fatty acid oxidation. A novel screening test. J Inherit Metab Dis 2002, 25:547-555.
77. Rhead W.J. Screening for inborn errors of fatty acid oxidation in cultured fibroblasts: an overview. Progress in Clinical and Biological Research. Fatty Acid Oxidation: Clinical, Biochemical and Molecular Aspects 1990, Vol. 321:365-382. Alan R. Liss, New York. K. Tanaka, P.M. Coates (Eds.).
78. Ribes A., Riudor E., Garavaglia B., et al. Mild or absent clinical signs in twin sisters with short-chain acyl-CoA dehydrogenase deficiency. Eur J Pediatr 1998, 157:317-320.
79. Rinaldo P., Matern D. Disorders of fatty acid transport and mitochondrial oxidation: challenges and dilemmas of metabolic evaluation. Genet Med 2000, 2:338-344.
80. Rinaldo P., Matern D., Bennett M.J. Fatty acid oxidation disorders. Annu Rev Physiol 2002, 64:477-502.
81. Roe C.R., Millington D.S., Norwood D.L., et al. 2,4-Dienoyl-coenzyme A reductase deficiency: a possible new disorder of fatty acid oxidation. J Clin Invest 1990, 85:1703-1707.
82. Roe C.R., Sweetman L., Roe D.S., et al. Treatment of cardiomyopathy and rhabodmyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest 2002, 110:259-269.
83. Ruitenbeek W., Poels P.J.E., Turnbull D.M., et al. Rhabdomyolysis and acute encephalopathy in late onset medium chain acyl-CoA dehydrogenase deficiency. J Neurol Neurosurg Psychiatry 1995, 58:209-214.
84. Sims H.F., Brackett J.C., Powell C.K., et al. The molecular basis of pediatric long chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with maternal acute fatty liver of pregnancy. Proc Natl Acad Sci U S A 1995, 92:841-845.
85. Solis J.O., Singh R.H. Management of fatty acid oxdation disorders: a survery of current treatment strategies. J Am Diet Assoc 2002, 102:1800-1803.
86. Souri M., Aoyama T., Orii K., et al. Mutation analysis of very-long-chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency: identification and characterization of mutant VLCAD cDNAs from four patients. Am J Hum Genet 1996, 58:97-106.
87. Spedding M. Activators and inactivators of Ca++ channels: new perspectives. J Pharmacol (Paris) 1985, 16:319-343.
88. Spedding M., Mir A.K. Direct activation of Ca++ channels by palmitoyl carnitine, a putative endogenous ligand. Br J Pharmacol 1987, 92:457-468.
89. Spiekerkoetter U., Bennett M.J., Ben-Zeev B., et al. Peripheral neuropathy, episodic myoglobinuria, and respiratory failure in deficiency of the mitochondrial trifunctional protein. Muscle Nerve 2004, 29:66-72.
90. Spiekerkoetter U., Lindner M., Santer R., et al. Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. J Inherit Metab Dis 2009, 32:488-497.
91. Stanley C.A., Hale D.E., Coates P.M. Medium-chain acyl-CoA dehydrogenase deficiency. Progress in Clinical and Biological Research. Fatty Acid Oxidation. Clinical, Biochemical, and Molecular Aspects 1990, Vol. 321:291-302. Alan R. Liss, New York. K. Tanaka, P.M. Coates (Eds.).
92. Stanley C.A., Deleeuw S., Coates P.M., et al. Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake. Ann Neurol 1991, 30:709-716.
93. Stanley C.A., Sunaryo F., Hale D.E., et al. Elevated plasma carnitine in the hepatic form of carnitine palmitoyltransferase-1 deficiency. J Inherit Metab Dis 1992, 15:785-789.
94. Strauss A.W. Genotype-phenotype correlations in mitochondrial trifunctional protein deficiency. Proceedings of the 7th International Congress of Inborn Errors of Metabolism 1997, 16. May 21-25, 07, Vienna, Austria, (Abstr).
95. Strauss A.W., Powell C.K., Hale D.E., et al. Molecular basis of human mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency causing cardiomyopathy and sudden death in childhood. Proc Natl Acad Sci U S A 1995, 92:10496-10500.
96. Taroni F., Verderio E., Dworzak F., et al. Identification of a common mutation in the carnitine palmitoyltransferase II gene in familial recurrent myoglobinuria patients. Nat Genet 1993, 4:314-320.
97. Tein I. Fatty acid oxidation and associated defects 1995, 269: 9-269: 37. Omnipress, Madison, WI.
98. Tein I. Fatty acid oxidation and associated defects 2000, 1-39. Omnipress, Madison, WI, 3AS.008.
99. Tein I. Metabolic disease in the fetus predisposes to maternal hepatic complications of pregnancy. Pediatr Res 2000, 47:6-8.
100. Tein I. Metabolic myopathies. Pediatric Neurology 2006, 2023-2073. Mosby-Yearbook, Philadelphia. 4th edn. K.F. Swaiman, S. Ashwal, D. Ferriero (Eds.).
101. Tein I., De Vivo D.C., Bierman F., et al. Impaired skin fibroblast carnitine uptake in primary systemic carnitine deficiency manifested by childhood carnitine-responsive cardiomyopathy. Pediatr Res 1990, 28:247-255.
102. Tein I., DiMauro S., De Vivo D.C. Recurrent childhood myoglobinuria. Adv Pediatr 1990, 37:77-117.
103. Tein I., De Vivo D.C., Hale D.E., et al. Short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency in muscle: a new cause for recurrent myoglobinuria and encephalopathy. Ann Neurol 1991, 30:415-419.
104. Tein I., DiMauro S., Rowland L.P. Myoglobinuria. Myopathies 1992, Vol. 18:553-593. Elsevier Science Publishers B.V., Amsterdam, (62). L.P. Rowland, S. DiMauro (Eds.).
105. Tein I., Donner E.J., Hale D.E., et al. Clinical and neurophysiologic response of myopathy and neuropathy in long-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency to oral prednisone. Pediatr Neurol 1995, 12:68-76.
106. Tein I., Halsam R.H., Rhead W.J., et al. Short-chain acyl-CoA dehydrogenase deficiency: a cause of ophthalmoplegia and multicore myopathy. Neurology 1999, 52:366-372.
107. Tein I., Vasjar J., MacMillan L., et al. Long-chain L-3-hydroxyacyl-coenzyme A dehydrogenase deficiency neuropathy: response to cod liver oil. Neurology 1999, 52:640-643.
108. Tein I., Elpeleg O., BenZe'ev B., et al. Short-chain acyl-CoA dehydrogenase gene mutation (c.319C>T) presents with clinical heterogeneity and is candidate founder mutation in individuals of Ashkenazi Jewish origin. Mol Genet Metab 2008, 93:179-189.
109. Thompson G.N., Hsu B.Y.L., Pitt J.J., et al. Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med 1997, 337:1203-1207.
110. Tonin P., Lewis P., Servidei S., et al. Metabolic causes of myoglobinuria. Ann Neurol 1990, 27:181-185.
111. Tonsgard J.H. Serum dicarboxylic acids in patients with Reye syndrome. J Pediatr 1986, 109:440-445.
112. Tonsgard J.H., Getz G.S. Effect of Reye's syndrome serum on isolated chinchilla liver mitochondria. J Clin Invest 1985, 76:816-825.
113. Treem W.R., Stanley C.A., Finegold D.N., et al. Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle and fibroblasts. N Engl J Med 1988, 319:1331-1336.
114. Tripp M.E., Katcher M.L., Peters H.A., et al. Systemic carnitine deficiency presenting as familial endocardial fibroelastosis. A treatable cardiomyopathy. N Engl J Med 1981, 305:385-390.
115. Tyni T., Pihko H., Kivela T. Ophthalmic pathology in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency caused by the G1528C mutation. Curr Eye Res 1998, 17:551-559.
116. Tyni T., Paetau A., Strauss A., et al. Mitochondrial fatty acid (beta) oxidation in the human eye and brain: implications for retinopathy of long-chain-3-hydroxyacyl-CoA dehydrogenase deficiency. Pediatr Res 2004, 56:744-750.
117. Uziel G., Garavaglia B., Cicer E., et al. Riboflavin-responsive glutaric aciduria type II presenting as a leukodystrophy. Pediatr Neurol 1995, 13:333-335.
118. Uauy R., Treen M., Hoffman D.R. Essential fatty acid metabolism and requirements during development. Semin Perinatol 1989, 13:118-130.
119. Verderio E., Cavadini P., Montermini L., et al. Carnitine palmitoyltransferase II deficiency: structure of the gene and characterization of two novel disease-causing mutations. Hum Mol Genet 1995, 4:19-29.
120. Wilson G.N., de Chadarevian J.P., Kaplan P., et al. Glutaric aciduria type II: review of the phenotype and report of an unusual glomerulopathy. Am J Med Genet 1989, 32:395-401.
121. Yamaguchi S., Indo Y., Coates P.M., et al. Identification of very-long-chain acyl-CoA dehydrogenase deficiency in three patients previously diagnosed with long-chain acyl-CoA dehydrogenase deficiency. Pediatr Res 1993, 34:111-113.
122. Zafeiriou D.I., Vargiami E., Mayapetek E., et al. 3-Hydroxy-3-methylglutaryl coenzyme a lyase deficiency with reversible white matter changes after treatment. Pediatr Neurol 2007, 37:47-50.
123. Ziadeh R., Hoffman E.P., Finegold D.N., et al. Medium chain acyl-CoA dehydrogenase deficiency in Pennsylvania: neonatal screening shows high incidence and unexpected mutation frequencies. Pediatr Res 1995, 37:675-678.